Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Hepcortespenlisimut-L (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Immunitor
- 25 Mar 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 25 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated